The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Pharmacology of a Central Nervous System Delivered 2′-O-Methoxyethyl–Modified Survival of Motor Neuron Splicing Oligonucleotide in Mice and Nonhuman Primates
Open accessAbstract
Spinal muscular atrophy (SMA) is a debilitating neuromuscular disease caused by the loss of survival of motor neuron (SMN) protein. Previously, we demonstrated that ISIS 396443, an antisense oligonucleotide (ASO) targeted to the SMN2 pre-mRNA, is a potent inducer of SMN2 exon 7 inclusion and SMN protein expression, and improves function and survival of mild and severe SMA mouse models. Here, we demonstrate that ISIS 396443 is the most potent ASO in central nervous system (CNS) tissues of adult mice, compared with several other chemically modified ASOs. We evaluated methods of ISIS 396443 delivery to the CNS and characterized its pharmacokinetics and pharmacodynamics in rodents and nonhuman primates (NHPs). Intracerebroventricular bolus injection is a more efficient method of delivering ISIS 396443 to the CNS of rodents, compared with i.c.v. infusion. For both methods of delivery, the duration of ISIS 396443-mediated SMN2 splicing correction is long lasting, with maximal effects still observed 6 months after treatment discontinuation. Administration of ISIS 396443 to the CNS of NHPs by a single intrathecal bolus injection results in widespread distribution throughout the spinal cord. Based upon these preclinical studies, we have advanced ISIS 396443 into clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many modifications can be applied to microRNA inhibitors and mimics, improving their stability, permeability, and specificity.”
From MiR-128-3p – a gray eminence of the human central nervous system (2024) · cites this paper as [195]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“intrathecal ASO injection to nonhuman primates led to accumulation of ASO in the cortical neuronal and glial cells (Rigo et al., 2014).”
From microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain (2015) · cites this paper as Rigo et al., 2014
The cited source says what the claim attributes to it.
In the citing paper
“Notably, intrathecal antisense oligonucleotides (ASO) injection successfully delivered ASO to the cortical cells in nonhuman primates [142].”
From MicroRNAs in brain cholesterol metabolism and their implications for Alzheimer's disease (2016) · cites this paper as [142]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., Le, T. T., Morales, P. R., Rich, M. M., Burghes, A. H. M., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1610 · Cited by 688
RetractedIdentification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Bénichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,995
Lorson, C. L., Hahnen, E., Androphy, E. J., & Wirth, B. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6307 · Cited by 1,536
Bennett, C. F., & Swayze, E. E. (2010) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,431
Self-citationCorrelation between severity and SMN protein level in spinal muscular atrophy
Lefebvre, S., Burlet, P., Liu, Q., Bertrandy, S., Clermont, O., Münnich, A., Dreyfuss, G., & Melki, J. (1997) · Nature Genetics · doi:10.1038/ng0797-265 · Cited by 1,100
Lunn, M. R., & Wang, C. H. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60921-6 · Cited by 1,010
Feldkötter, M., Schwarzer, V., Wirth, R., Wienker, T. F., & Wirth, B. (2002) · The American Journal of Human Genetics · doi:10.1086/338627 · Cited by 1,005
Monani, U. R. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.7.1177 · Cited by 951
Kordasiewicz, H. B., Stanek, L. M., Wancewicz, E. V., Mazur, C., McAlonis, M. M., Pytel, K. A., Artates, J. W., Weiss, A., Cheng, S. H., Shihabuddin, L. S., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.05.009 · Cited by 770
Self-citationMonani, U. R. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.3.333 · Cited by 745
Flagged first, then by citations
1 of the 56 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–283 of 283
RNA-Based Therapies for Neurodegenerative Diseases.
Ayala, Y. M., & Nguyen, A. D. (2021) · PubMed Central · Cited by 8
Antisense-Oligonucleotide Modulation of SMN2 Pre-mRNA Splicing
Hua, Y., & Krainer, A. R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803685-3.00018-5 · Cited by 7
Self-citationMuiños-Bühl, A., Rombo, R., Janzen, E., Ling, K., Hupperich, K., Rigo, F., Bennett, C. F., & Wirth, B. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105795 · Cited by 12
Self-citationKhurshid, S., Venkataramany, A. S., Montes, M., Kipp, J. F., Roberts, R. D., Wein, N., Rigo, F., Wang, P.-Y., Cripe, T. P., & Chandler, D. S. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200908 · Cited by 7
Self-citationCornelissen, L., Donado, C., Yu, T. W., & Berde, C. B. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.664710 · Cited by 7
Gazzola, M., & Martinat, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015291 · Cited by 7
Metz, T., Welling, M. M., Suidgeest, E., Nieuwenhuize, E., de Vlaam, T., Curtis, D., Hailu, T. T., van der Weerd, L., & van Roon‐Mom, W. (2024) · Nucleic Acid Therapeutics · doi:10.1089/nat.2023.0018 · Cited by 6
Real-world evidence on nusinersen treatment of persons with SMA: a focused review
Matesanz, S. E., & Finkel, R. S. (2025) · Journal of Neuromuscular Diseases · doi:10.1177/22143602251385045 · Cited by 6
Leckie, J., Wu, S. Z., Standell, T., & Yokota, T. (2025) · Genes · doi:10.3390/genes16121468 · Cited by 7
Aartsma-Rus, A. M., & Takeda, S. (2025) · Journal of Neuromuscular Diseases · doi:10.1177/22143602251317422 · Cited by 6
LncRNA Functional Screening in Organismal Development
Li, Y., Zhai, H., Tong, L., Wang, C., Xie, Z., & Zheng, K. (2023) · Non-Coding RNA · doi:10.3390/ncrna9040036 · Cited by 6
Therapeutic potential of orphan drugs for the rare skeletal muscle diseases
Swiderski, K., & Lynch, G. S. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1085858 · Cited by 7
Ohmura, T., Saeki, S., Ogiwara, K., Tobita, K., Yan, L., & Torii, S. (2018) · Folia Pharmacologica Japonica · doi:10.1254/fpj.152.147 · Cited by 6
Proof-of-Concept: Antisense Oligonucleotide Mediated Skipping of Fibrillin-1 Exon 52
Cale, J. M., Greer, K., Fletcher, S., & Wilton, S. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073479 · Cited by 6
Tau biology, biomarkers, and therapeutics
Frost, B. E., Kolb, H. C., Algeciras‐Schimnich, A., Betthauser, T. J., DeVos, S. L., Edelmayer, R. M., Elwood, F., Fleisher, A., Henley, D. B., Horie, K., et al. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70165 · Cited by 7
The Chemistry of Oligonucleotide Delivery
Rozema, D. B. (2017) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2017.07.003 · Cited by 5
Kusaka, S., Miyake, Y., Tokumaru, Y., Morizane, Y., Tamaki, S., Akiyama, Y., Sato, F., & Murata, I. (2022) · Life · doi:10.3390/life12111786 · Cited by 5
Synthesis and biophysical properties of tetravalent PEG-conjugated antisense oligonucleotide
Chowdhury, T. R., Taufiq, T., Ishida, K., Islam, M. A., Kasahara, Y., Osawa, T., & Obika, S. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.117149 · Cited by 5
Valencia, A., Bieber, V. L. R., Bajrami, B., Marsh, G., Hamann, S., Wei, R., Ling, K., Rigo, F., Arnold, H. M., Golonzhka, O., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.624051 · Cited by 5
Self-citationThe Munich Meeting: Medical Maturation, More Mechanisms, and Milasen
Aartsma-Rus, A. M., & Watts, J. K. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2019.29003.aar · Cited by 5
Stratton, M. P., Centa, J. L., Swier, V. J., Pfeifer, W. L., Booth, C. D., Albert, K., Hunyara, J. L., Rechtzigel, M. J., Duelli, F. J., Leppert, H. G., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf1141 · Cited by 4
Self-citationSel, E. K., Gkrinia, E. M. M., Roncato, R., Vitezić, D., Јаnkovic, S., & Belančić, A. (2025) · Journal of International Medical Research · doi:10.1177/03000605251397777 · Cited by 5
Bravo‐Hernández, M., Mazur, C., Chen, H., Fradkin, L., Searcy, J., Burel, S. A., Kelly, M., Bruening, D., O’Rourke, J. G., Cai, Y., et al. (2026) · Nucleic Acids Research · doi:10.1093/nar/gkag057 · Cited by 9
Self-citationXu, B., Wei, C., Hu, X., Li, W., Huang, Z., Que, C., Qiu, J., Li, C., & Xiong, H. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.869230 · Cited by 4
NADPH oxidase 4 inhibition is a complementary therapeutic strategy for spinal muscular atrophy
Khoury, M. E., Biondi, O., Bruneteau, G., Sapaly, D., Bendris, S., Bézier, C., Clerc, Z., Akar, E. A., Weill, L., Eid, A. A., et al. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1242828 · Cited by 4
Antisense Oligonucleotide Therapeutics for Neurodegenerative Disorders
Testa, C. M. (2021) · Current Geriatrics Reports · doi:10.1007/s13670-020-00341-7 · Cited by 4
An Insight on RNA Based Therapeutics and Vaccines: Challenges and Opportunities
Batra, K., Maan, S., & Sehrawat, A. (2021) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026621666211118095451 · Cited by 4
Hernandez, M. B., Mazur, C., Chen, H., Fradkin, L., Searcy, J., Burel, S. A., Kelly, M. E., Bruening, D., O’Rourke, J. G., Cai, Y., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.13.638138 · Cited by 4
Self-citationArtificial miRNA-mediated reduction of SNCA for the treatment of α-synucleinopathies
Elmer, B. M., Wischhof, E., Chan, T., Mahendran, T., Ardinger, J. A., Richards, B., Liu, D., Bladon, J. H., He, Y., Jackson, R., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.11.017 · Cited by 3
Elevating microRNA levels by targeting biogenesis with steric-blocking antisense oligonucleotides
Havens, M. A., Hinrich, A. J., Rigo, F., & Hastings, M. L. (2024) · RNA · doi:10.1261/rna.080021.124 · Cited by 3
Self-citationMolecular basis and therapy of spinal muscular atrophy
Szczerba, A., Śliwa, A., Żarowski, M., & Jankowska, A. (2018) · Child Neurology · doi:10.20966/chn.2018.55.429 · Cited by 3
(2015) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.3109/21678421.2015.1089039 · Cited by 4
Recent applications of RNA therapeutic in clinics
Thi, H. T. H., & Than, V. T. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.12.015 · Cited by 3
Intracellular Delivery of Antisense Oligonucleotides by Tri‐Branched Cyclic Disulfide Units
Lyu, F., Hakariya, H., Hiraoka, H., Li, Z., Matsubara, N., Soo, Y., Hashiya, F., Abe, N., Shu, Z., Nakamoto, K., et al. (2024) · ChemMedChem · doi:10.1002/cmdc.202400472 · Cited by 3
Lee, L., Gollen, R., Fathallah, A. M., Gao, L., & Patil, S. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2172 · Cited by 3
Desai, D. A., Ette, M. E., Shah, D. K., & Mager, D. E. (2025) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2025.100167 · Cited by 2
Aartsma-Rus, A. M. (2023) · Synlett · doi:10.1055/a-2211-6490 · Cited by 2
Beyond muscle: Delivering RNA therapeutics to the CNS in Duchenne muscular dystrophy
Vacca, O., Nagy, C., & Goyenvalle, A. (2025) · Journal of Neuromuscular Diseases · doi:10.1177/22143602251360668 · Cited by 2
Elsheikh, B., Kolb, S. J., & Kissel, J. T. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813866-3.00022-9 · Cited by 2
Antisense: Progress Towards Gene-Directed Cancer Therapy☆
Crooke, S. T., & MacLeod, A. R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.98738-5 · Cited by 2
Intracerebroventricular Delivery in Mice for Motor Neuron Diseases
Nizzardo, M., & Rizzuti, M. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6817-6_19 · Cited by 2
Alternative Splicing and Human Disease
Stamm, S. (2017) · Wiley eBooks · doi:10.1002/9780470015902.a0021435.pub2 · Cited by 2
Tissue distribution pharmacokinetics of intrathecal U1 adaptor oligonucleotide in mice
Satti, M., Prasad, K., Patel, Y., Poulathas, D., Walker, L., Paghdal, E., Gunderson, S., & Yu, L. (2025) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2025.100220 · Cited by 1
Wang, X., Zheng, Y., Lu, J., Li, X., Chen, S., Xue, Y., Hu, S., Peng, G., Zhang, F., Zhao, X., et al. (2026) · Annals of Physical and Rehabilitation Medicine · doi:10.1016/j.rehab.2025.102080 · Cited by 1
Genetic medicines for epilepsy: unlocking new avenues for seizure control
Wee, I. C., Przybyla, M., Touma, J., Ittner, L. M., & van Eersel, J. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1768550 · Cited by 1
Gopi, S., Prethiba, S., Chandhru, M., Namasivayam, S. K. R., & Arockiaraj, J. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.05.008 · Cited by 2
RNA‐Binding Proteins: Function, Biological Mechanisms, and Therapeutic Opportunities
Li, L., Yan, X., Ji, Q., & Zhang, H. (2026) · MedComm · doi:10.1002/mco2.70938 · Cited by 1
Spinal Muscular Atrophy: Entering the Treatment Age
Kichula, E. A., Yum, S. W., & Brandsema, J. F. (2018) · Current Pediatrics Reports · doi:10.1007/s40124-018-0150-2 · Cited by 1
Antisense oligonucleotide drugs for neurological and neuromuscular disease
Lane, R. M., & Bennett, C. F. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813955-4.00017-9 · Cited by 1
Self-citationAntisense Oligonucleotides: Concepts and Pharmaceutical Applications
Araya, A. K., Arias, D., Coto, K., López, M. R., Rivera, J., & Mora, J. J. (2023) · Borneo Journal of Pharmacy · doi:10.33084/bjop.v6i1.2092 · Cited by 1
Spinal Muscular Atrophy: An Overview
Ross, S. D., Rudowski, S., & Kanungo, S. (2023) · OBM Genetics · doi:10.21926/obm.genet.2302182 · Cited by 1
Zhou, L., Bi, J., Chang, S., Bai, Z., Yu, J., Wang, R., Li, Z., Zhang, X., Chou, J. J., & Pan, L. (2024) · Angewandte Chemie · doi:10.1002/ange.202415272 · Cited by 1
A Manual for Genome and Transcriptome Engineering
Doctor, Y., Sanghvi, M., & Mali, P. (2024) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2024.3494715 · Cited by 1
Translational research—from basic science to an approved therapeutic—an overview
Saporito, M. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820007-0.00034-9 · Cited by 1
Waldrop, M. A., Kolb, S. J., Kissel, J. T., & Elsheikh, B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19176-3.00014-5 · Cited by 1
Rescue of blood coagulation Factor VIII exon-16 mis-splicing by antisense oligonucleotidesPreprint
Tse, V., Chacaltana, G., Gutierrez, M. E., Forino, N. M., Jimenez, A. G., Tao, H., Phong, H., Oh, C., Chary, P., Quesada, I., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.31.535160 · Cited by 1
Self-citationModulation of Abnormal Splicing of RNA Diseases by Small Chemical Compounds
Kataoka, N. (2018) · Springer eBooks · doi:10.1007/978-981-10-8372-3_8
A review of potential RNA therapeutics for Machado-Joseph disease
Acosta, G., Goyal, S., & Aoh, Q. L. (2019) · BIOS · doi:10.1893/0005-3155-89.3.97
Post‐Transcriptional Regulation of Gene Expression and Human Genetic Disease
Sterrett, M. C., & Corbett, A. H. (2019) · Wiley eBooks · doi:10.1002/9780470015902.a0028665
Development of a molecular therapy for the SOD1 familial variant of ALS
Smith, R. A., Miller, T. M., Cleveland, D. W., & Bennett, F. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816475-4.00006-9
Oligonucleotide, Therapy, and Applications
Aliño, S. F., & Sendra, L. (2022) · MDPI eBooks · doi:10.3390/books978-3-0365-3056-7
Dürr, A. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.731217459.793552254
Fletcher, S. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732900592.793560211
Disney, M. D. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736176320.793563807
Targeted delivery of therapeutic oligonucleotides in pancreatic cancer
Iris, Y. (2022) · Journal of Biology and Medicine · doi:10.17352/jbm.000028
Nucleic Acid Pharmaceutical Agents
Kohnken, R. A., Harbison, C. E., Klein, S., & Engelhardt, J. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821047-5.00017-8
Li, M., & Kühn, B. (2024) · STAR Protocols · doi:10.1016/j.xpro.2024.103094
Antisense oligonucleotide drugs for neurological and neuromuscular diseases
Lane, R. M., & Bennett, C. F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19041-4.00039-x
Self-citation4) Antisense Therapeutics for Spinal Muscular Atrophy
Sahashi, K., & Katsuno, M. (2024) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.113.1581
Longitudinal PET Imaging of the Effects of a D 2 Dopamine Receptor Antisense Oligonucleotide
Cheataini, F., Bouillot, C., Valdebenito, M., Courault, P., Lancelot, S., Bouvard, S., Zimmer, L., & Vidal, B. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00115
Ahammad, R. U., Quach, B., Salehi, S. N., Rissman, R. A., & Spencer, B. J. (2026) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2026.100304 · Cited by 2
Okamoto, K. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03552-0
Phenotypic screening for small molecules that lower PrP in cultured cells
Frei, J. A., Reidenbach, A. G., Xu, L. M., Gopalakrishnan, R. M., Casalana, D., Sprague, D. A., Bray, M. A., Wang, A. Q., Laversenne, V., Erickson, B., et al. (2026) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2026.104111
van de Langerijt, K. A., Kibria, M. G., Villa, G. R., & Mineo, M. (2026) · Cells · doi:10.3390/cells15141251
Harikai, N., Kuba, K., Ichinose, Y., Hayashi, A., Tanaka, Y., Zaima, K., Uchida, Y., Yoshida, T., Sezaki, H., & Inoué, T. (2026) · BioTechniques · doi:10.1080/07366205.2026.2716053
Safety and toxicity assessment of antisense oligonucleotides in brain-relevant human cellular models
Zanjko, L. C., Andrés-Santamaria, R., Balogh, A., van Roon-Mom, W. M. C., & Dinnyés, A. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103062
Antisense oligonucleotides against Il6ra ameliorate cancer cachexia in mice
Wang, Y., Sun, Q., Zheng, W., Han, L., Zhang, Q., Krainer, A. R., & Li, B. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.08.028
Self-citationYin, L., Ren, R., Leo, C., & Lu, Y. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108439
Spinal muscular atrophy as a blueprint for precision therapy in neuromuscular disease
Cetin, B., Aliciaslan, M., Erbasan, E., Cesur, B., & Şanlıoğlu, S. (2026) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2026.10072
Aiyedun, D., Rogers, S. F., Taha, D. M., & Balasubramanian, M. (2026) · Clinical Genetics · doi:10.1111/cge.70267
Metadata
- Authors
- Rigo, F., Chun, S. J., Norris, D. A., Hung, G., Lee, S., Matson, J., Fey, R. A., Gaus, H., Hua, Y., Grundy, J. S., Krainer, A. R., Henry, S. P., & Bennett, C. F.
- Affiliations
- Cold Spring Harbor Laboratory (US)
- ORCID
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2014-07
- Volume
- 350
- Issue
- 1
- Pages
- 46-55
- ISSN
- 0022-3565 (ISSN-L)
- PMC
- PMC4056267
- OpenAlex
- W2090804804
- Cited by
- 283
- References
- 56
- Citations by year
- 2026: 16 · 2025: 19 · 2024: 22 · 2023: 25 · 2022: 24 · 2021: 25 · 2020: 35 · 2019: 24 · 2018: 23 · 2017: 23 · 2016: 21 · 2015: 21 · 2014: 5
- FWCI
- 11.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Pharmacology and Experimental Therapeutics (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- Funders
- Spinal Muscular Atrophy Foundation
- National Institute of General Medical Sciences (R37-GM42699, R37GM042699, R01GM042699)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- spinal muscular atrophy, antisense oligonucleotides, SMN protein, central nervous system delivery, intrathecal administration, pharmacokinetics, pharmacodynamics, non-human primates, modified oligonucleotides, preclinical pharmacology
- MeSH terms
- Animals, Brain, Female, Injections, Intraventricular, Macaca fascicularis, Male, Muscular Atrophy, Spinal, Oligonucleotides, RNA Splicing, Mice, Knockout, Oligodeoxyribonucleotides, Antisense, Mice, Survival of Motor Neuron 2 Protein, Infusions, Intraventricular
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
